Dyadic International (DYAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Jun, 2026Executive summary
Received notification from Nasdaq regarding potential delisting due to failure to meet minimum bid price and continued listing standards as of June 18, 2026.
Company failed to regain compliance with the $1.00 minimum bid price and did not meet the $5 million shareholders' equity requirement by June 17, 2026.
Additional deficiencies include not meeting $2.5 million in shareholders' equity, $35 million market value, or $500,000 net income from continuing operations.
Plans to request a hearing before an independent Nasdaq panel, which will temporarily stay any suspension or delisting action.
Maximum extension for compliance runs through December 15, 2026, but there is no assurance of regaining compliance or avoiding delisting.
Risk oversight and compliance
Forward-looking statements highlight risks such as net losses, regulatory acceptance, commercialization challenges, competition, and capital needs.
Risks also include reliance on third parties, government regulations, intellectual property, and ability to comply with Nasdaq standards.
Reference to detailed risk factors in annual and quarterly SEC filings.
Shareholder rights and capital structure
Failure to comply with Nasdaq listing standards may adversely affect liquidity, market price, and ability to raise capital.
Delisting could impact the company's ability to operate as a going concern.
Latest events from Dyadic International
- All proposals passed, with strategic focus on commercial growth and Nasdaq compliance efforts.DYAI
AGM 202618 Jun 2026 - Commercial stage reached with six product launches, global distribution, and early recurring revenues.DYAI
Lytham Partners Spring 2026 Investor Conference28 May 2026 - Commercializing animal-free proteins with scalable platforms and recurring revenues across key markets.DYAI
Sidoti Micro-Cap Virtual Conference20 May 2026 - Commercial-stage protein innovator drives growth with animal-free products and global partnerships.DYAI
Investor presentation20 May 2026 - Q1 2026 revenue rose 182% to $1.11M, with net loss narrowing and global expansion underway.DYAI
Q1 202619 May 2026 - Shareholders will vote on director election, reverse stock split, auditor ratification, and executive pay.DYAI
Proxy filing12 May 2026 - C1 platform delivers rapid, high-yield, animal-free biologics with proven safety and global validation.DYAI
Investor presentation1 May 2026 - Virtual meeting to vote on director, reverse split, auditor, and executive pay; board urges approval.DYAI
Proxy filing1 May 2026 - Net loss widened to $7.36M on lower revenue, with expanded commercialization and partnerships.DYAI
Q4 202525 Mar 2026